Abstract
The effect of High-Dose Methylprednisolone (HD-MP) treatment on Peripheral Blood (PB) and Cerebrospinal Fluid (CSF) immune parameters was investigated in 9 patients with relapsing-progressive Multiple Sclerosis (MS). Short-time effects included reduction of the percentage of CD3+, CD4+ and CD4+CD45RA+ PB lymphocytes and increase in CD3-CD56+ cells. At the end of the treatment, only increase in PB CD19+ and in CSF CD8+, CD8+CD28+ and decrease of CSF CD4+CD45RA- and serum IL2R levels were observed. No changes in CD11a+CD4+, CD18+CD14+ PB cells were observed after treatment. The results further stress the complex and multifaceted action of HD-MP on immune parameters.
MeSH terms
-
Adult
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD8 Antigens / immunology
-
Cell Adhesion Molecules / immunology
-
Cell Adhesion Molecules / metabolism
-
Cerebrospinal Fluid / cytology
-
Female
-
Fluorescent Antibody Technique
-
Humans
-
Immunoglobulin G / immunology
-
Interleukin-2 / metabolism
-
Leukocyte Count / drug effects
-
Lymphocyte Subsets / drug effects
-
Lymphocyte Subsets / immunology
-
Male
-
Methylprednisolone / administration & dosage*
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Monocytes / drug effects
-
Monocytes / immunology
-
Multiple Sclerosis / blood
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / immunology*
Substances
-
CD8 Antigens
-
Cell Adhesion Molecules
-
Immunoglobulin G
-
Interleukin-2
-
Methylprednisolone